UPDATE: MLV Raises TG Therapeutics Price Target Following TG-1101 And TGR-1202 Data At ASH
In a research report released this morning, MLV analyst Arlinda Lee maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price target of $22, based on positive data and progress for the company’s TGR-1201 and TG-1101.
The following bullets contain some highlights from the report:
- TGTX’s TGR-1202 potentially has best AE profile, enabling combination therapy.
- TG-1101 (ublituximab) plus Ibrutinib highly active in r/r CLL and MCL.
- TG-1101 + TGR-1202 demonstrates potent activity in CLL and NHL.
- The new $22 price target is based on Sum-of-Parts Probability-Adjusted NPV analysis: TG-1101 ~$14/share (65% probability, $544M peak sales) and TGR-1202 ~$8/share (45% probability, $425M peak sales).
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Arlinda Lee has a total average return of 6.0% and a 63.6% success rate. Lee has a 30.0% average return when recommending TGTX, and is ranked #1453 out of 3412 analysts.